公开(公告)号：US20210214424A1

公开(公告)日：2021-07-15

申请号：US17054994

申请日：2019-05-16

申请人： CHANG GUNG MEMORIAL HOSPITAL, LINKOU ,  ACADEMIA SINICA

发明人： Alice YU ,  Han-Chung WU ,  John YU

IPC分类号： C07K16/18 ,  A61K47/68 ,  A61P35/00

摘要： The present invention provides monoclonal antibodies or the antigen-binding portion thereof, that bind to a feto-embryonic dedifferentiated antigen, such as Leucine-rich Repeat Neuronal Protein 1 (LRRN1), a surface glycoprotein that is expressed abundantly on the surface of human embryonic stem cells prior to differentiation into embryoid bodies. Also disclosed herein are the uses of the novel LRRN1 antibodies.

公开(公告)号：US20210236647A1

公开(公告)日：2021-08-05

申请号：US16062274

申请日：2017-01-11

申请人： Academia Sinica

发明人： Han-Chung WU ,  Chen-Yun YEH

IPC分类号： A61K47/62 ,  A61K47/69 ,  A61K9/127 ,  A61P35/00 ,  A61K49/00 ,  A61K49/18

摘要： An isolated or a synthetic targeting peptide comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 8 is disclosed. The targeting peptide may be conjugated to a component selected from the group consisting of polymeric micelles, lipoprotein-based drug carriers, nanoparticle drug carriers, a chemotherapeutic agent, a micelle, a liposome, dendrimers, a polymer, a lipid, an oligonucleotide, a peptide, a polypeptide, a protein, a prostate cancer cell, a stem cell, and an imaging agent. Also disclosed are a kit for imaging and detecting the presence of prostate cancer cells in vivo or in vitro, and a composition for treating prostate cancer, inhibiting prostate cancer cell growth, inducing prostate cancer cell cytotoxicity, and/or increasing the survival rate in a prostate cancer patient.

公开(公告)号：US20210088514A1

公开(公告)日：2021-03-25

申请号：US16832396

申请日：2020-03-27

申请人： Academia Sinica

发明人： Ying-Chih CHANG ,  Han-Chung WU ,  Po-Yuan TSENG ,  Jen-Chia WU

IPC分类号： G01N33/543 ,  C07K17/14 ,  C07K16/30 ,  G01N33/574 ,  G01N1/40

摘要： This invention relates to a surface coating for capture circulating rare cells, comprising a nonfouling composition to prevent the binding of non-specific cells and adsorption of serum components; a bioactive composition for binding the biological substance, such as circulating tumor cells; with or without a linker composition that binds the nonfouling and bioactive compositions. The invention also provide a surface coating for capture and purification of a biological substance, comprising a releasable composition to release the non-specific cells and other serum components; a bioactive composition for binding the biological substance, such as circulating tumor cells; with or without a linker composition that binds the releasable and bioactive compositions. The present invention also discloses a novel microfluidic chip, with specific patterned microstructures to create a flow disturbance and increase the capture rate of the biological substance.

公开(公告)号：US20180030097A1

公开(公告)日：2018-02-01

申请号：US15549457

申请日：2016-01-27

申请人： Academia Sinica

发明人： Han-Chung WU ,  Chung-Tao TANG

IPC分类号： C07K14/005 ,  G01N33/569 ,  A61K39/39 ,  C07K16/10 ,  A61K39/12 ,  C12N7/00

CPC分类号： C07K14/005 ,  A61K39/12 ,  A61K39/39 ,  A61K2039/505 ,  A61K2039/53 ,  A61K2039/55505 ,  A61K2039/575 ,  C07K16/1081 ,  C07K2317/34 ,  C07K2317/76 ,  C12N7/00 ,  C12N2770/24122 ,  C12N2770/24123 ,  C12N2770/24134 ,  C12N2770/24151 ,  C12N2770/24171 ,  G01N33/56983 ,  G01N2333/185 ,  G01N2469/20 ,  Y02A50/386 ,  Y02A50/53

摘要： Isolated mutant dengue virus E protein variants are disclosed. The variant comprises an amino acid sequence that is at least 80% identical to SEQ ID NO: 1 and has one or more amino acid residue substitutions at position corresponding to Asn8 (N8), Arg9 (R9), Val12 (V12) and/or Glu13 (E13). The variant may comprise an amino acid sequence that is at least 90% identical to the SEQ ID NO: 1 and lack an infection-enhancing antibody-binding motif comprising the amino acid sequence of SEQ ID NO: 28 at domain I. An isolated nucleic acid sequence encoding the variant, a plasmid expressing the variant, a plasmid expressing a virus-like particle comprising the variant, a DNA vaccine, and a method of detecting the presence of a dengue virus in a biological sample are also disclosed.

公开(公告)号：US20170199184A1

公开(公告)日：2017-07-13

申请号：US15378938

申请日：2016-12-14

申请人： Academia Sinica

发明人： Ying-Chih CHANG ,  Han-Chung WU ,  Po-Yuan TSENG ,  Jen-Chia WU

IPC分类号： G01N33/543 ,  G01N33/574

CPC分类号： G01N33/54386 ,  C07K16/30 ,  C07K17/14 ,  G01N1/405 ,  G01N33/54393 ,  G01N33/57492

摘要： This invention relates to a surface coating for capture circulating rare cells, comprising a nonfouling composition to prevent the binding of non-specific cells and adsorption of serum components; a bioactive composition for binding the biological substance, such as circulating tumor cells; with or without a linker composition that binds the nonfouling and bioactive compositions. The invention also provide a surface coating for capture and purification of a biological substance, comprising a releasable composition to release the non-specific cells and other serum components; a bioactive composition for binding the biological substance, such as circulating tumor cells; with or without a linker composition that binds the releasable and bioactive compositions. The present invention also discloses a novel microfluidic chip, with specific patterned microstructures to create a flow disturbance and increase the capture rate of the biological substance.

公开(公告)号：US20160280794A1

公开(公告)日：2016-09-29

申请号：US15011544

申请日：2016-01-30

申请人： Academia Sinica

发明人： Chi-Huey WONG ,  Chung-Yi WU ,  Che MA ,  Han-Chung WU

IPC分类号： C07K16/30 ,  C07K16/40 ,  C07K16/24 ,  C07K16/28

CPC分类号： C07K16/30 ,  A61K45/06 ,  C07K16/1018 ,  C07K16/18 ,  C07K16/241 ,  C07K16/2887 ,  C07K16/32 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2319/00 ,  C12N9/24 ,  C12P21/005 ,  C12Y302/01 ,  C12Y302/01051

摘要： The present disclosure relates to compositions and methods of use comprising antibodies or binding fragments thereof further comprising universal Fc glycoforms.

摘要翻译： 本公开涉及包含抗体或其结合片段的组合物和使用方法，其还包含通用Fc糖形式。

公开(公告)号：US20150202315A1

公开(公告)日：2015-07-23

申请号：US14499201

申请日：2014-09-28

申请人： Academia Sinica

发明人： Han-Chung WU ,  Chien-Hsun Wu

IPC分类号： A61K47/48 ,  A61K31/704 ,  A61K31/437 ,  C07K7/08

CPC分类号： A61K47/48246 ,  A61K31/437 ,  A61K31/704 ,  A61K47/48215 ,  A61K47/48238 ,  A61K47/48815 ,  A61K47/60 ,  A61K47/62 ,  A61K47/64 ,  A61K47/6911 ,  C07K7/08

摘要： A peptide targeted conjugate is disclosed. The conjugate comprises: (a) an isolated or a synthetic targeting peptide of less than 15 amino acid residues in length, comprising an amino acid sequence having at least 90% identity to a sequence selected from the group consisting of SEQ ID NOs: 1, 2 and 3; and (b) a component, to which the targeting peptide is conjugated, the component being selected from the group consisting of a drug delivery vehicle, an anti-cancer drug, a micelle, a nanoparticle, liposomes, a polymer, a lipid, an oligonucleotide, a peptide, a polypeptide, a protein, a cell, an imaging agent, and a labeling agent. The conjugate may further comprise an anti-cancer agent encapsulated within the drug delivery vehicle. Compositions and methods of treating cancer are also disclosed.

摘要翻译： 公开了一种靶向靶向的缀合物。 缀合物包含：（a）长度小于15个氨基酸残基的分离或合成的靶向肽，其包含与选自SEQ ID NO：1，SEQ ID NO：1，SEQ ID NO： 2和3; 和（b）靶向肽共轭的组分，所述组分选自药物递送载体，抗癌药物，胶束，纳米颗粒，脂质体，聚合物，脂质， 寡核苷酸，肽，多肽，蛋白质，细胞，成像剂和标记剂。 缀合物还可包含包封在药物递送载体内的抗癌剂。 还公开了治疗癌症的组合物和方法。

公开(公告)号：US20240174765A1

公开(公告)日：2024-05-30

申请号：US18281977

申请日：2022-03-22

申请人： Academia Sinica

发明人： Han-Chung WU ,  Hsin-Jung LI

IPC分类号： C07K16/40 ,  A61P35/04 ,  G01N33/573 ,  G01N33/574

CPC分类号： C07K16/40 ,  A61P35/04 ,  G01N33/573 ,  G01N33/57492 ,  G01N2333/988

摘要： The present invention relates to antibodies that bind to ENO1 and applications thereof. The applications encompass therapies and diagnostics of diseases or disorders associated with ENO1 activation and progression thereof using such antibodies. Specifically, the antibodies of the present invention bind to ENO1 on the surface of cancer cells and are useful in reducing cancer cell growth and metastasis and prolonging survival time. The antibodies of the present invention may also be used in detecting ENO1, diagnosis and prognosis of cancer and monitoring cancer progression. The present invention also provides a method for screening for a candidate agent for cancer therapy.

公开(公告)号：US20220313840A1

公开(公告)日：2022-10-06

申请号：US17616002

申请日：2020-05-31

申请人： Academia Sinica

发明人： Han-Chung WU ,  Yi-Ping WANG ,  I-Ju LIU ,  Meng-Jhe CHUNG

IPC分类号： A61K47/69 ,  C07K16/28 ,  A61K47/68 ,  A61P35/00

摘要： The present application relates to ligands targeted to epidermal growth factor receptor (EGFR) and compositions for use in treating tumors. Specifically, a ligand targeted to EGFR is disclosed. The ligand comprises a heavy chain variable domain and a light chain variable domain. The ligand may be selected from the group consisting of a single chain variable fragment, a fusion protein, a monoclonal antibody, and an antigen-binding fragment thereof. The ligand may be conjugated to a liposome or a nanoparticle that encapsulates at least one chemotherapeutic agent to form a ligand-targeted liposomal or nanoparticle drug. Also disclosed are conjugates and formulations for use in treating tumors such as squamous cell carcinoma of head and neck. A method for making a ligand-targeted liposomal drug is also disclosed. The drug may be a chemotherapeutic agent selected from the group consisting of doxorubicine and vinorelbine.

公开(公告)号：US20200299329A1

公开(公告)日：2020-09-24

申请号：US16823356

申请日：2020-03-19

申请人： Academia Sinica

发明人： Han-Chung WU ,  Yuan-Sung KUO

IPC分类号： C07K7/06 ,  A61K47/64 ,  A61K38/43

摘要： Disclosed herein is a biomolecule comprising a synthetic peptide for targeting thrombus, a pharmaceutical composition comprising the same, and uses thereof in the treatment of thromboembolism-related diseases. According to embodiments of the present disclosure, the synthetic peptide having the amino acid sequence of SEQ ID NO: 1, 2, or 3 exhibits a binding affinity and specificity to thrombus. Thus, the synthetic peptide may serve as a targeting element for delivering a therapeutic agent (e.g., an anticoagulant agent or a thrombolytic agent) to the thrombus thereby improving the therapeutic safety and efficacy of the therapeutic agent.